Entasis Shares Rally On Positive Data From Drug-Resistant Bacterial Infection Candidate

  • Entasis Therapeutics Holdings Inc ETTX announced topline results from its Phase 3 ATTACK trial of sulbactam-durlobactam (SUL-DUR) versus colistin in patients with infections caused by Acinetobacter baumannii. 
  • Colistin (polymyxin E) is an antibiotic medication used as a last resort for multidrug-resistant Gram-negative infections.
  • Related: Why Are Entasis Therapeutics Shares Moving Higher On Thursday?
  • SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections and demonstrated statistical non-inferiority versus colistin.
  • SUL-DUR also achieved a statistically significant reduction in nephrotoxicity.
  • SUL-DUR mortality was 19.0% (12/63) compared to 32.3% (20/62) in the colistin arm (treatment difference of -13.2%).
  • A statistically significant difference in clinical cure at Test of Cure (TOC) was observed with 61.9% in the SUL-DUR arm compared to 40.3% in the colistin arm.
  • Overall adverse events in the safety population were comparable between treatment groups.
  • The company is targeting marketing application submission in mid-2022.
  • Entasis will conduct a conference call today at 8:00 am ET.
  • Price Action: ETTX shares gained 14.8% at $3.57 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechLong IdeasNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsPhase 3 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!